Scarica l'app Stockscreener
5.09
3.96%
-0.21
Dopo l'orario di chiusura:
5.09
Cingulate Inc Borsa (CING) Ultime notizie
CING Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerProfit Announcement - dars.gov.et
Enterprise value to revenue forward of Cingulate Inc. – NASDAQ:CING - TradingView
Cingulate, Inc. Warrant 2021-03.12.26 on Cingulate Financial Disclosures & SEC Filings - TradingView
Form 4 Cingulate Inc For: 2 July By Investing.com - Investing.com Canada
Cingulate (CING) EVP and CSO Raul Silva receives grant of 3,885 stock options - Stock Titan
Cingulate added to Russell 3000E Index - Investing.com
Cingulate added to Russell 3000E Index By Investing.com - Investing.com Canada
Index addition puts Cingulate (NASDAQ: CING) into the Russell 3000E - Stock Titan
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® - Yahoo Finance
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc. (CING) Surges 8.78% as Momentum Builds Near Key Resistance LevelPrice Momentum Stocks - dars.gov.et
CING News | CINGULATE INC (NASDAQ:CING) - ChartMill
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Growth Benchmark - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Index - marketscreener.com
Cingulate, Inc. Actuals & Estimates (NASDAQ:CING) - TradingView
CING Forecast — Price Target — Prediction for 2027 - TradingView
Cingulate Inc (CINGW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CING Stock Price, Quote & Chart - ChartMill
CING Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports Wider-than-Expected Loss - dars.gov.et
Cingulate Inc (CINGW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CINGW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CINGW) Institutional Confidence - TradingKey
Cingulate Inc (CINGW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CINGW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CING) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CING) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Inc (CING) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CING) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CING) Institutional Confidence - TradingKey
Cingulate Inc (CING) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CINGW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CINGW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CINGW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - markets.businessinsider.com
Cingulate Secures First U.S. Patent for CTx-1301 ADHD Drug, Extending Exclusivity to 2042 - Minichart
Cingulate issued U.S. patent for CTx-1301, exclusivity extended into Dec 2042 - TradingView
US patent extends Cingulate (NASDAQ: CING) CTx-1301 ADHD exclusivity - Stock Titan
Cingulate Inc. Warrants (CINGW) Narrows to Key Level: A Tight Trading Range EmergesDemand Zone - dars.gov.et
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday - Sahm
Cingulate director Hargroves buys $490,271 of common stock By Investing.com - Investing.com India
CING Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues pipeline development - newsline.com
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase - TipRanks
CING Maintained by Ascendiant Capital -- Price Target Lowered to $52 - GuruFocus
Cingulate director Hargroves buys $490,271 of common stock - Investing.com
Cingulate (CING) director-linked LLC buys shares, warrants as options granted - Stock Titan
Cingulate (CING) director reports initial share and warrant holdings - Stock Titan
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) Following FDA Complete Response Letter - citybuzz -
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan
FDA slaps CRL on Cingulate’s CTx-1301 NDA - The Pharma Letter
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):